Syndax Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Syndax Pharmaceuticals Inc SNDX.OQ reported a quarterly adjusted loss of 98 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -85 cents. The mean expectation of ten analysts for the quarter was for a loss of $1.33 per share. Wall Street expected results to range from $-4.08 to -74 cents per share.

• Revenue was $20.04 million​; analysts expected $14.43 million.

• Syndax Pharmaceuticals Inc's reported EPS for the quarter was a loss of 98 cents​.

• The company reported a quarterly loss of $84.85 million.

• Syndax Pharmaceuticals Inc shares had risen by 11.8% this quarter and gained 3.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 29.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $37.00

This summary was machine generated from LSEG data May 5 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)